Fan L, et al. - In this investigation, researchers studied the dose-effect relationship of ilaprazole [kind of benzimidazole proton-pump inhibitor] and rabeprazole in the treatment of duodenal ulcer (DU). For this double-blind, parallel, randomized study, subjects over 18 years of age were treated with rabeprazole 10 mg or ilaprazole 10 mg/5 mg for 4 weeks with at least one endoscopically confirmed active non-malignant DU. The study was finally completed by a total of 390 patients. According to findings, ilaprazole 5 mg in the treatment of DU is not lower than rabeprazole 10 mg and a dose-effect relationship between 5 mg and 10 mg ilaprazole has been found. After treatment, the majority of patients (80%) became asymptomatic.